Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (NASDAQ:ALNY) and Natera (NASDAQ:NTRA).
Alnylam Pharma (ALNY)
In a report released today, David Lebovitz from Morgan Stanley maintained a Hold rating on Alnylam Pharma, with a price target of $87. The company’s shares closed yesterday at $90.09, close to its 52-week low of $86.95.
According to TipRanks.com, Lebovitz is a 4-star analyst with an average return of 27.4% and a 57.1% success rate. Lebovitz covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Akebia Therapeutics.
Currently, the analyst consensus on Alnylam Pharma is a Strong Buy with an average price target of $147.75.
See today’s analyst top recommended stocks >>
Natera (NTRA)
Morgan Stanley analyst Steve Beuchaw maintained a Buy rating on Natera today and set a price target of $41. The company’s shares closed yesterday at $22.14.
According to TipRanks.com, Beuchaw is a 4-star analyst with an average return of 13.5% and a 66.7% success rate. Beuchaw covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA Inc, Myriad Genetics, and Danaher Corp.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Natera with a $29.67 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
